Showing results (111-120 of 127) with videos related to
Sort By:
Pageof 13
Cancer|April 13, 2018
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signaturesDavid R Spigel, Howard A Burris, F Anthony Greco, et al.Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Ian W Flinn, David R Spigel, et al.Lung Cancer (Amsterdam, Netherlands)|March 25, 2018
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)John D Hainsworth, David M Waterhouse, Kent C Shih, et al.Cancer|September 7, 2002
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trialF Anthony Greco, James R Gray, Dana S Thompson, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancerDavid R Spigel, John D Hainsworth, Jitendra G Gandhi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.Clinical Lung Cancer|October 10, 2007
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research NetworkF Anthony Greco, David R Spigel, Michel E Kuzur, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerDavid R Spigel, Howard A Burris, F Anthony Greco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancerRonald B Natale, Sumitra Thongprasert, F Anthony Greco, et al.Pageof 13